Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a.

In this study, we investigated the value of measurement of the chemokine CXCL1 in clinical management of hepatocellular carcinoma (HCC) and its possible role in the molecular pathogenesis of HCC. High CXCL1 expression predicted recurrence in HCC patients and promoted tumor progression in both in vivo and in vitro experimental systems. Overexpression of CXCL1 increased mitochondrial metabolism and activated the epithelial-to-mesenchymal transition (EMT).

Liver transplantation in adults with portal vein thrombosis: Data from the China Liver Transplant Registry.

Objectives: Portal vein thrombosis (PVT) is a common complication in patients with liver cirrhosis. During liver transplantation (LT), PVT may complicate the procedure and lead to a poor prognosis. The aim of this study is to evaluate patients enrolled in the China Liver Transplant Registry, to understand the influence of PVT to the LT recipients.

Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.

Aim: To investigate the value of chaperonin containing TCP1, subunit 3 (CCT3) to predict the prognosis of patients with hepatocellular carcinoma (HCC) and determine its function in HCC progression.

Methods: CCT3 expression levels were examined in human non-cancerous liver tissues and a variety of HCC cell lines by quantitative real-time PCR and immunoblotting. CCT3 expression was suppressed by small interfering RNA.

Esophagogastric devascularization without splenectomy in portal hypertension: safe and effective?

Background: Esophagogastric variceal hemorrhage is a life-threatening complication of portal hypertension. In this study, we compared the therapeutic effect of a novel surgical procedure, esophagogastric devascularization without splenectomy (EDWS), with the widely used modified esophagogastric devascularization (MED) with splenectomy for the treatment of portal hypertension.

Methods: Fifty-five patients with portal hypertension were included in this retrospective study.

Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.

Background: Glypican-3 (GPC-3) is frequently overexpressed in hepatocellular carcinoma (HCC). Recent studies have shown that GPC-3 is a highly efficient diagnostic biomarker of HCC and an indicator of poor prognosis in HCC patients who have undergone hepatectomy. However, its prognostic value in patients with HBV-associated HCC after liver transplantation (LT) is not clear.

De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Purpose: The aim of this study is to evaluate the incidence of de novo malignancy after liver transplantation (LT) and compare with those among the general Chinese population.

Methods: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study. All data of medical records and follow up were retrospectively reviewed.

Hepatocellular carcinoma recurrence is an independent risk factor for HB recurrence after liver transplantation.

Background/aims: To confirm the relationship between hepatitis B recurrence and Hepatocellular carcinoma recurrence.

Methodology: Data from 340 patients undergoing liver transplantation for HBV-related liver disease were retrospectively evaluated. Clinically relevant variables were analyzed using univariate models.

Ileo-colonic intussusception secondary to small-bowel lipomatosis: a case report.

Intestinal lipomatosis is a rare disease with an incidence at autopsy ranging from 0.04% to 4.5%.

Histological differentiation predicts post-liver transplantation survival time.

Objectives: Although liver transplantation is the most effective long-term treatment for hepatocellular carcinoma (HCC), the recurrence of HCC remains an issue. Current research examining recurrence after liver transplantation primarily focuses on patients' clinical characteristics. There is no consensus regarding the factors that may relate to predict the survival time and recurrence rates for patients with hepatitis B virus (HBV)-associated HCC transplantation using clinicopathological analysis.

[Management of hepatic artery related complications and its outcome during liver transplantation].

Objective: To explore the experience of hepatic arterial reconstruction and management of its complications.

Methods: The clinical data of 570 consecutive orthotopic liver transplantation patients performed from May 2001 to May 2009 in Peking University People's Hospital were analyzed retrospectively in order to summarize the key factors of hepatic arterial reconstruction and the experience of management of its complications.

Results: Arterial complications developed in 18 (3.

Graft versus host disease after liver transplantation: a case report.

In documenting clinical experience in the diagnosis and treatment of graft versus host disease (GVHD), we retrospectively analyzed data of one case that has developed GVHD after liver transplantation. This patient exhibited fever, skin rash, and diarrhea on day 9 after liver transplantation. His liver function was normal.

[Liver transplantation for the patients with end stage liver disease and portal vein thrombosis].

Objective: To investigate the outcome of liver transplantation(LT) for end stage liver disease with portal vein thrombosis (PVT) in different processes.

Methods: Data from 308 patients who underwent LT from July 2004 to February 2008 were retrospectively assessed. The processes of varies grades of PVT during LT were analyzed and estimated for whether the outcome of LT was different between patients with or without PVT.

[Analysis of 565 cases of liver transplantation at a single transplantation center].

Objective: To determine the preventative and curative strategies after liver transplantation by investigating the risk factors on prognosis.

Methods: The data of 565 consecutive patients who underwent orthotopic liver transplantation were retrospectively analyzed with the survival rate and complication morbidity.

Results: The follow-up time ranges from 3 to 104 months of all the 565 patients after liver transplantation.